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Abstract
Background: Transport protein particle (TRAPP) is a supramolecular protein complex that functions in localizing
proteins to the Golgi compartment. The TRAPPC11 subunit has been implicated in muscle disease by virtue of
homozygous and compound heterozygous deleterious mutations being identified in individuals with limb girdle
muscular dystrophy and congenital muscular dystrophy. It remains unclear how this protein leads to muscle
disease. Furthermore, a role for this protein, or any other membrane trafficking protein, in the etiology of the
dystroglycanopathy group of muscular dystrophies has yet to be found. Here, using a multidisciplinary approach
including genetics, immunofluorescence, western blotting, and live cell analysis, we implicate both TRAPPC11 and
another membrane trafficking protein, GOSR2, in α-dystroglycan hypoglycosylation.
Case presentation: Subject 1 presented with severe epileptic episodes and subsequent developmental
deterioration. Upon clinical evaluation she was found to have brain, eye, and liver abnormalities. Her serum
aminotransferases and creatine kinase were abnormally high. Subjects 2 and 3 are siblings from a family unrelated
to subject 1. Both siblings displayed hypotonia, muscle weakness, low muscle bulk, and elevated creatine kinase
levels. Subject 3 also developed a seizure disorder. Muscle biopsies from subjects 1 and 3 were severely dystrophic
with abnormal immunofluorescence and western blotting indicative of α-dystroglycan hypoglycosylation.
Compound heterozygous mutations in TRAPPC11 were identified in subject 1: c.851A>C and c.965+5G>T. Cellular
biological analyses on fibroblasts confirmed abnormal membrane trafficking. Subject 3 was found to have
compound heterozygous mutations in GOSR2: c.430G>T and c.2T>G. Cellular biological analyses on fibroblasts from
subject 3 using two different model cargo proteins did not reveal defects in protein transport. No mutations were
found in any of the genes currently known to cause dystroglycanopathy in either individual.
Conclusion: Recessive mutations in TRAPPC11 and GOSR2 are associated with congenital muscular dystrophy and
hypoglycosylation of α-dystroglycan. This is the first report linking membrane trafficking proteins to
dystroglycanopathy and suggests that these genes should be considered in the diagnostic evaluation of patients
with congenital muscular dystrophy and dystroglycanopathy.
Keywords: TRAPPC11, GOSR2, Golgi, Dystroglycanopathy, Dystroglycan, Muscular dystrophy, Glycosylation,
Membrane traffic
* Correspondence: michael.sacher@concordia.ca; steven-moore@uiowa.edu
†Austin A. Larson, Peter R. Baker II, Miroslav P. Milev, Michael Sacher and
Steven A. Moore contributed equally to this work.
2Department of Biology, Concordia University, Montreal, Canada
3Department of Pathology Carver College of Medicine, The University of
Iowa, Iowa City, IA, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Larson et al. Skeletal Muscle  (2018) 8:17 
https://doi.org/10.1186/s13395-018-0163-0
Background
Dystroglycanopathies are a group of muscular dystrophies
resulting from abnormal glycosylation of α-dystroglycan
(α-DG) that leads to reduced binding affinity for extracel-
lular matrix proteins [1]. The clinical phenotypes span a
broad range from the congenital muscular dystrophies
(CMDs) with brain and eye malformations to adult-onset
limb-girdle muscular dystrophy (LGMD) [2]. Dystroglycan
is encoded by DAG1 and is cleaved into α-DG and β-DG
after translation [3]. DAG1 is widely expressed in different
human tissues, consistent with the multi-organ pheno-
types of many individuals with the most severe forms of
dystroglycanopathy [4].
Mutations in DAG1 itself as well as 17 other genes
have been reported in patients with dystroglycanopathy.
These include glycosyltransferases (POMT1, POMT2,
POMGNT1, POMGNT2, B3GALNT2, B3GNT1, LARGE,
TMEM5), a kinase (POMK), five genes encoding en-
zymes necessary for dolichol-P-mannose (dol-P-man)
synthesis (DOLK, DPM1, DPM2, DPM3, and GMPPB),
and three genes encoding proteins necessary for joining
the α-DG-linked core glycan structure with the distal
ligand-binding region of the structure via a ribitol
phosphate disaccharide (FKTN, FKRP, ISPD) [5]. To
date, no membrane trafficking proteins have been impli-
cated in dystroglycanopathies.
In this study, we report clinical, histopathological,
biochemical, and molecular genetic data on two families
with CMD and hypoglycosylation of α-DG. Two genes,
TRAPPC11 and GOSR2, that each have a role in mem-
brane trafficking in the biosynthetic pathway have been
implicated as candidate dystroglycanopathy genes. They
represent the first membrane trafficking proteins impli-
cated in α-DG hypoglycosylation. Since TRAPPC11
mutations have been reported in a number of individuals
suffering from a muscular dystrophy, and these individ-
uals also display membrane trafficking defects in cul-
tured fibroblasts, this gene should be considered in the
diagnostic evaluation of patients with CMD.
Case presentation
Family 1
Subject 1 presented with status epilepticus in the setting
of a vomiting illness at 6 months of age. Magnetic reson-
ance imaging (MRI) of the brain showed bilateral multi-
focal restricted diffusion of the cortex, the cerebral white
matter, and the pons (Fig. 1a). Her serum aminotransfer-
ases were elevated with alanine aminotransferase (ALT)
of ~ 1600 U/L and aspartate aminotransferase (AST) ~
400 U/L as well as a prolonged prothrombin time of
20.7 s (normal range is 12–15 s), consistent with syn-
thetic liver dysfunction. The approximately 4:1 ALT to
AST ratio was consistent over multiple measurements.
Creatine kinase (CK) at initial presentation was 3500 U/
L. She had significant regression of development with
loss of rolling and sitting, loss of fine motor and verbal
skills, and inability to feed orally after this illness.
MRI of the lower extremities showed high signal on
short tau inversion recovery (STIR) sequences of the
deep and superficial posterior compartments bilaterally
(Fig. 1c). Skeletal muscle and liver biopsies were
obtained at 9 months of age. Liver biopsy showed micro-
vesicular steatosis (Fig. 1d, e). Skeletal muscle showed an
active dystrophic process (Fig. 1g) and hypoglycosylation
of α-DG by both immunofluorescence and western blot-
ting (Fig. 2). In contrast, α-DG in cultured fibroblasts was
indistinguishable from control fibroblasts in on-cell and in
WGA glycoprotein western blots (data not shown). This is
not uncommon and has been reported in the case of other
genes involved in dystroglycanopathy [6, 7].
The patient had several subsequent acute infectious
illnesses with seizures and neurological regression.
Follow-up brain MRI at 15 months of age showed
marked progressive volume loss (Fig. 1b). Glycosylation
analysis of transferrin and ApoCIII proteins in serum by
affinity chromatography-mass spectrometry (Mayo
Medical Laboratory) as well as by MALDI-TOF mass
spectrometry (Emory Genetics Laboratory) was normal.
In her last evaluation, at 3 years and 6 months of age,
she was areflexic with limited antigravity strength and
severe hypotonia. She fed exclusively via gastrostomy
tube with no verbal communication. Seizures were well
controlled on levetiracetam monotherapy. CK remained
elevated with values as high as 19,000 U/L. She had mild
hepatomegaly and aminotransferases were still signifi-
cantly elevated with 4:1 ALT to AST ratio, but there was
no coagulopathy or hyperbilirubinemia. She chronically
required noninvasive positive pressure ventilation with
sleep. After multiple hospital admissions for viral
respiratory infections, she underwent immunological
evaluation and was found to have impaired natural killer
cell function on multiple repeated analyses. She did not
have peripheral neuropathy, cataracts, alacrima, achala-
sia, renal disease, hearing loss, or cholestasis.
Exome trio sequencing showed compound heterozy-
gous rare variants in trans in TRAPPC11 (NM_021942):
c.851A>C (p.Q284P) and c.965+5G>T (intron 9 splice
site disruptor). The p.Q284P missense mutation was
absent from the Exome Aggregation Consortium (ExAC)
database, and c.965+5G>T was present in 2/119,770
alleles [8]. The latter mutation resulted in a transcript
that lacks exon 9 and the first 88 bases of exon 10
(Fig. 3a) and is predicted to result in an in-frame dele-
tion of amino acids 278–351 (p.I278_Q351del). Cultured
fibroblasts had greatly reduced levels of TRAPPC11
(Fig. 3b) suggesting the p.Q284P protein and the pre-
dicted p.I278_Q351del protein are unstable. These fibro-
blasts showed a delay in the maturation of the marker
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protein VSVG-GFP ts045 (Fig. 3c, d). Analysis of
live-cell trafficking revealed a delay in the release of
VSVG-GFP ts045 from the Golgi (Fig. 3e, f ) as well as a
delay in arrival of a Golgi marker (sialyl
transferase-SBP-GFP) from the endoplasmic reticulum
(Fig. 3g, h). The delayed release of protein from the
Golgi is consistent with the initial findings reported by
Bögershausen et al. in LGMD2S patients with
TRAPPC11 mutations [9], and the delayed arrival of
protein to the Golgi is consistent with the findings of
Scrivens et al. [10].
Family 2
Subject 2 presented for medical evaluation at age
6 months for hypotonia. She was found to have CK
values of up to ~ 5000 U/L. She developed absence
seizures at age 2 years. She had steadily progressive
muscle weakness. On examination at age 4 years and
9 months, she was areflexic. She had low muscle bulk
and myopathic facial appearance and did not have anti-
gravity strength. She had fine nystagmus but otherwise
intact extraocular movements. MRI of the brain was
normal at ages 2 and 4 years. She died due to respiratory
failure at age 5 years.
Subject 3 is the younger sister of subject 2. She was
noted to have muscle weakness and hypotonia at
3 months of age. At 9 months, she had antigravity
strength only. Serum CK value was 1760 U/L. At
19 months, skeletal muscle biopsy was obtained showing
an active dystrophic process (Fig. 1h) and hypoglycosyla-
tion of α-DG by both immunofluorescence and western
blotting (Fig. 2). In contrast, α-DG in cultured fibro-
blasts was indistinguishable from control fibroblasts in
on-cell and in WGA glycoprotein western blots (data
not shown). Furthermore, the VSVG-GFP membrane
trafficking assay kinetics as well as arrival of the Golgi
Fig. 1 Subjects 1 and 3 display brain, liver, and muscle abnormalities. a Diffusion-weighted (B1000) MRI showing restricted diffusion of the medial
occipital cortex and underlying white matter at 6 months of age in subject 1 at the time of initial presentation. b Fluid-attenuated inversion
recovery (FLAIR) MRI for subject 1 at 15 months notable for marked cerebral volume loss. c Short tau inversion recovery (STIR) shows symmetric
high signal in the posterior compartments of the legs of subject 1 at 12 months of age. Subject 1 has microvesicular steatosis of the liver; light
microscopy hematoxylin and eosin (d) and electron microscopy (e). Note the lipid accumulations marked by the arrows in e. f–h Muscle biopsies
from control (f), subject 1 (g), and subject 3 (h) were stained with hematoxylin and eosin. Dystrophic features are present in subjects 1 and 3. The
size bar denotes 50 μm in d and f–h. The size bar denotes 5 μm in e
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marker was indistinguishable from control fibroblasts
(Fig. 3c–f ).
At age 2.5 years, she developed a seizure disorder
characterized as focal seizures but later as both focal and
generalized, which often became intractable and re-
quired hospitalization. Evaluation showed no evidence of
nystagmus and ocular range of motion was full. There
were no focal deficits and her cranial nerves were nor-
mal. She demonstrated severe weakness and muscular
hypotonia. MRI of the brain showed diffuse volume loss
resulting in ex vacuo ventriculomegaly. EEG at 2 years
and 7 months of age showed runs of spike and wave
discharges originating in the occipital lobe which were
exacerbated by photic stimuli. Head circumference was
at the 30th centile, height at the 10th centile, and weight
below the 1st centile.
At 3.5 years of age, she developed episodes of vomiting
and apparent abdominal pain. This led to the detection
of elevated ALT of up to 700 U/L. An extensive evalu-
ation for infectious, anatomical, autoimmune, and meta-
bolic etiologies of liver disease was nondiagnostic.
Physical exam revealed findings similar to her sister.
Apart from her sister, there is no family history of
neuromuscular disease. The subject is now 6 years of
age with medically refractory epilepsy and progressive
severe muscle weakness. Clinical exome trio sequencing
was performed, and no relevant sequence variants were
initially reported. In a targeted sequencing panel, subject
3 was found to have compound heterozygous rare vari-
ants in GOSR2 (NM_001012511): c.430G>T (p.G144W)
and c.2T>G. Retrospective evaluation of GOSR2 in the
whole exome sequencing (WES) data confirmed that
both variants were present in subject 3 and were in
trans. Extensive re-evaluation of seizure and dystrogly-
canopathy loci in the WES failed to identify any other
pathologic variants. The GOSR2 p.G144W missense
variant is a previously reported disease-causing muta-
tion and is present in 5/121,408 alleles in the ExAC
database with no homozygous individuals. The second
variant (c.2T>G) is present in 1/18,808 alleles in the
ExAC database [8]. The mutation is likely to result in
the use of an alternate start codon with elimination of
Fig. 2 Subjects 1 and 2 display abnormalities in both α-dystroglycan staining and glycosylation. Control muscle or muscle taken from subject 1 (S1)
and subject 3 (S3) were stained for alpha dystroglycan using VIA4-1 antibody (a) or β-DG (b). Note the reduced staining for α-DG but not β-DG in
subjects 1 and 3. The size bar denotes 50 μm for all panels in a and b. c Western blot analysis of muscle tissue from control and subjects 1 and 3.
Samples were probed with peptide-specific antibody AF6868 and the glycoepitope-specific antibody IIH6 as indicated. The location of α-DG and β-DG
is indicated. Note that control shows a higher molecular size immunoreactive species for α-DG with both antibodies while S1 and S3 show a more
heterogeneous species of much smaller molecular size, suggesting hypoglycosylation of the protein
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Fig. 3 (See legend on next page.)
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18 amino acids from the amino-terminus of the protein
according to MutationTaster2 and is presumed to be
pathogenic as a result [11].
Discussion and conclusions
In this report, we show that mutations in two genes
encoding proteins involved in membrane trafficking,
TRAPPC11 and GOSR2, are associated with CMD and
dystroglycanopathy. Biallelic mutations in TRAPPC11
were initially reported as the etiology of LGMD2S in
2013 [9] and have since been associated with a variety of
multisystemic phenotypic findings including intellectual
disability, seizures, microcephaly, cerebral atrophy,
cataracts, alacrima, achalasia, hepatic steatosis, and
cholestatic liver disease, in addition to muscular
dystrophy [9, 12–15]. Comparisons between subject 1
and all published mutations in TRAPPC11 and associ-
ated phenotypes are summarized in Table 1. Our study
now adds two new mutations with functional validation
and categorizes TRAPPC11-related disease as a
dystroglycanopathy.
TRAPPC11 dysfunction may contribute to disease
pathophysiology in several ways. Extensive functional
studies of cultured fibroblasts were conducted by
Bögershausen et al. [9]. They demonstrated that cells
had abnormally fragmented and diffuse Golgi; delayed
traffic out of the Golgi and the proteins LAMP1 and
LAMP2 were found to be abnormally glycosylated.
TRAPP (transport protein particle) forms several related
multisubunit trafficking complexes (MTCs) that partici-
pate in the tethering of vesicles to target membranes,
including vesicles associated with the Golgi [10]. Since
the Golgi is the major site of protein glycosylation in the
cell [16], defects in Golgi morphology and traffic can
result in protein glycosylation defects. Recently, abnor-
mal glycosylation of serum transferrin was described in
a patient with compound heterozygous mutations in
TRAPPC11, consistent with a type 2 disorder of glyco-
sylation [12]. We were unable to detect abnormalities in
glycosylation of serum transferrin using two different com-
monly employed methods. Thus, while TRAPPC11-related
disease is a disorder of glycosylation, analysis of glycoepi-
topes of secreted proteins may not be a sensitive test for
diagnostic purposes.
The zebrafish model of TRAPPC11-related disease shows
generalized impairment of N-linked glycosylation as well as
depletion of lipid-linked oligosaccharides (LLOs) [17]. The
inability to synthesize dolichol-P-mannose (dol-P-man), a
lipid-linked saccharide, is a known cause of dystroglycano-
pathy [7]. Expression of multiple glycosylation-related genes
(including the known etiologies of dystroglycanopathy
gmppb, dpm1, dpm2, and dpm3) showed significant com-
pensatory upregulation in the trappc11 fish [17]. Interest-
ingly, TRAPPC11 siRNA knockdown in HeLa cells had a
specific inhibitory effect on glycosylation that was not
present with knockdown of other components of the
TRAPP complex. This led to the conclusion that
TRAPPC11 may have another function that is independent
of its role in vesicle transport and led to speculation that
impaired LLO synthesis may be the most relevant function
of TRAPPC11 in the process of protein glycosylation [17].
Finally, trappc11 zebrafish mutations were shown to lead to
fatty liver via a pathological activation of the unfolded
protein response. This may be relevant to subject 1 as well
as the other reported individuals with hepatopathy and
TRAPPC11-related disease [13]. Taken together, several
mechanisms for the role of TRAPPC11 in muscular and
hepatic phenotypes are known and can explain many
clinical features of subject 1.
Human mutations in GOSR2 were first reported in
2011 in six individuals with the same homozygous
missense mutation (c.430G>T) who had progressive
myoclonus epilepsy (PME), ataxia, scoliosis, and mildly
elevated serum CK (see Table 1 for a comparison
between subjects 2 and 3 with all reported GOSR2 muta-
tions) [18]. All individuals were areflexic in early child-
hood and were non-ambulatory by adolescence or early
adulthood. Muscle histology and EMG were normal. An
additional eleven individuals with similar clinical presen-
tations and the same homozygous mutation were
reported in 2013 and 2014 [19, 20]. The maximum CK
value reported in any of the patients was 2467 U/L.
(See figure on previous page.)
Fig. 3 TRAPPC11 compound heterozygous mutations affect membrane trafficking in patient fibroblasts. a mRNA was collected from control and
subject 1 (S1), converted to cDNA and amplified by PCR using oligonucleotides annealing to exons 8 and 11. The amplicons were sequenced
and found to represent exons 8-9-10-11 (higher molecular size amplicon) and exons 8-part of 10-11 (lower molecular size amplicon). b Lysates
from control and subject 1 (S1) fibroblasts were probed for TRAPPC11 and tubulin as a loading control. c Fibroblasts were infected with VSVG-
GFP ts045, and the protein was arrested in the endoplasmic reticulum (ER) by shifting the cells to 40 °C. The protein was synchronously released
from the ER upon downshifting the temperature to 32 °C, and the acquisition of Endoglycosidase H (EndoH) resistance was assayed at the times
indicated. A representative western blot is displayed, and quantification of a minimum of three such blots is shown in d. e The same assay as in
b was performed on live cells and the arrival and release of the GFP signal was quantified over time. Representative images from the movies are
displayed in e, and quantification of the signal in the Golgi region is shown in f. To more accurately measure ER-to-Golgi trafficking, the RUSH
assay [36] was performed using ST-SBP-GFP with the Ii hook (g). Images were acquired over time in live cells upon addition of biotin to initiate
release of the protein from the ER. Quantification of the signal in the Golgi is displayed in h. Size bars in e and g denote 25 μm. Error bars
represent SEM from a minimum of three replicates in d. N values for f and h are indicated in the figure
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There was no specific assessment of α-DG glycosylation
in their muscle biopsies. Subjects 2 and 3 in our study
have a much more severe phenotype. Since CMD
represents the severe end of the clinical spectrum of
GOSR2-related disease and PME represents the milder
end of the spectrum, the new c.2T>G mutation resulting
in CMD reported in our study likely cause more severe
perturbation of Golgi function than the common
c.430G>T mutation. It remains unclear which aspect of
Golgi function is affected since a membrane trafficking
defect in neither the VSVG-GFP marker protein nor a
resident Golgi enzyme was detected. Future studies
should examine the trafficking of Golgi-localized
glycosyl transferases that are responsible for α-DG
processing.
GOSR2 encodes a Golgi Qb-SNARE (soluble N-ethyl-
maleimide-sensitive factor attachment protein receptor)
protein. In the cell, GOSR2 localizes to the cis-Golgi and
mediates docking and fusion of vesicles originating from
the ER. There is precedent for Golgi dysfunction leading
to diseases manifesting with abnormal glycosylation and
multisystemic disease. Examples include the disease
caused by mutations in genes that encode the COG
(conserved oligomeric Golgi) complex, an MTC that
localizes to the Golgi [21]. Additionally, an individual
has been described with CMD due to homozygous mu-
tations in GOLGA2, a golgin protein that also impacts
Golgi function [22]. The potential for a link between
aberrant Golgi trafficking and dystroglycanopathy stems
from an experiment employing a modified virus that
required normally glycosylated α-DG for cell entry.
Knockouts of known dystroglycanopathy genes in
cultured fibroblasts resulted in impaired viral cell entry.
Among the other knockouts shown to impair viral cell
entry were those cells with mutations in several of the
COG complex genes [23].
Dystroglycanopathies result in muscular dystrophy due
to dysfunctional linkage of the sarcolemma to the extra-
cellular matrix. This linkage occurs via α-DG and relies
on the synthesis of a complex LARGE-glycan for normal
function [5]. Since the initial descriptions of dystroglyca-
nopathy [1, 24–26], a variety of molecular mechanisms
of the diseases have been discovered. Specific glycosyl-
transferases such as POMT1/POMT2 are required to
construct the core glycan structure that is linked to
α-DG [25, 26]. Mutations in DOLK, DPM1, DPM2,
DPM3, and GMPPB likely lead to a deficiency of
dol-P-man (a lipid-linked monosaccharide) resulting in
abnormal N-linked glycosylation as well as the O-linked
mannosylation defect that results in dystroglycanopathy
[6, 7, 27–31]. LARGE synthesizes the extracellular
matrix binding region of the glycan structure (matrigly-
can) that is distal to the core region [32]. Most recently,
FKTN, FKRP, and ISPD have been implicated in the
addition of ribitol phosphate molecules to link the core
and ligand-binding regions of the α-DG glycan structure
[33–35]. Our study suggests that TRAPPC11 and
GOSR2 are also involved in the trafficking and glycosyla-
tion of dystroglycan in the Golgi. This represents the
first report of an association between these genes and
α-DG hypoglycosylation. It remains to be seen if other
GOSR2 mutations associate with similar cellular and
clinical phenotypes. Given the number of individuals with
TRAPPC11 mutation-associated muscular dystrophy, it may
be prudent for this gene to now be considered in the diag-
nostic evaluation of patients with dystroglycanopathy.
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